Drugs that contain Omadacycline Tosylate

1. Drug name - NUZYRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7553828 PARATEK PHARMS INC 9-aminomethyl substituted minocycline compounds
Jun, 2023

(7 months from now)

US7326696 PARATEK PHARMS INC Amino-methyl substituted tetracycline compounds
Sep, 2023

(11 months from now)

US8383610 PARATEK PHARMS INC Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline
Sep, 2030

(7 years from now)

CN1649582A PARATEK PHARMS INC Amino-Methyl Substituted Tetracycline Compounds
May, 2012

(10 years ago)

CN1690047B PARATEK PHARMS INC 9-Substituted Minocycline Compounds
Aug, 2014

(8 years ago)

CN1690047A PARATEK PHARMS INC 9-Substituted Minocycline Compounds
Aug, 2014

(8 years ago)

CN105348138A PARATEK PHARMS INC Salt And Polymorph Of Tetracycline Compound
Aug, 2018

(4 years ago)

CN100473644C PARATEK PHARMS INC 9-Substituted Minocycline Compounds
Jun, 2021

(1 year, 3 months ago)

CN1471509A PARATEK PHARMS INC 9-Substituted Minocycline Compounds
Jun, 2021

(1 year, 3 months ago)

CN102105058B PARATEK PHARMS INC Salt And Polymorph Of Tetracycline Compound
May, 2029

(6 years from now)

CN102105058A PARATEK PHARMS INC Salts And Polymorphs Of A Tetracycline Compound
May, 2029

(6 years from now)

CN104844472B PARATEK PHARMS INC Salts And Polymorphs Of A Tetracycline Compound
May, 2029

(6 years from now)

CN104844472A PARATEK PHARMS INC Salts And Polymorphs Of A Tetracycline Compound
May, 2029

(6 years from now)

IN200402212P4 PARATEK PHARMS INC Amino-Methyl Substituted Tetracycline Compounds
Mar, 2023

(5 months from now)

IN228816B PARATEK PHARMS INC Amino-Methyl Substituted Tetracycline Compound
Mar, 2023

(5 months from now)

EP2308832A1 PARATEK PHARMS INC 9-Substituted Minocycline Compounds
Jun, 2021

(1 year, 3 months ago)

EP2308832B1 PARATEK PHARMS INC 9-Substituted Minocycline Compounds
Jun, 2021

(1 year, 3 months ago)

EP2308832B8 PARATEK PHARMS INC 9-Substituted Minocycline Compounds
Jun, 2021

(1 year, 3 months ago)

EP1301467A2 PARATEK PHARMS INC 9-Substituted Minocycline Compounds
Jun, 2021

(1 year, 3 months ago)

EP1301467B1 PARATEK PHARMS INC 9-Substituted Minocycline Compounds
Jun, 2021

(1 year, 3 months ago)

EP1679305A1 PARATEK PHARMS INC 9-Substituted Minocycline Compounds
Jun, 2021

(1 year, 3 months ago)

EP1679305B1 PARATEK PHARMS INC 9-Substituted Minocycline Compounds
Jun, 2021

(1 year, 3 months ago)

EP2296464A4 PARATEK PHARMS INC Salts And Polymorphs Of A Tetracycline Compound
May, 2029

(6 years from now)

EP2296464A1 PARATEK PHARMS INC Salts And Polymorphs Of A Tetracycline Compound
May, 2029

(6 years from now)

EP2807926B1 PARATEK PHARMS INC Salts And Plymorphs Of A Tetracycline Compound
May, 2029

(6 years from now)

EP2807926A1 PARATEK PHARMS INC Salts And Plymorphs Of A Tetracycline Compound
May, 2029

(6 years from now)

EP2296464B1 PARATEK PHARMS INC Salts And Polymorphs Of A Tetracycline Compound
May, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10124014 PARATEK PHARMS INC Minocycline compounds and methods of use thereof Mar, 2029

(6 years from now)

US9724358 PARATEK PHARMS INC Minocycline compounds and methods of use thereof Mar, 2029

(6 years from now)

US9265740 PARATEK PHARMS INC Minocycline compounds and methods of use thereof Mar, 2029

(6 years from now)

US9314475 PARATEK PHARMS INC Oral and injectable formulations of tetracycline compounds Mar, 2031

(8 years from now)

US10111890 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and uses thereof Aug, 2037

(14 years from now)

US10835542 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) Oct, 2037

(15 years from now)

US10383884 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) Oct, 2037

(15 years from now)

Treatment: Treatment of bacterial skin and skin structure infection; Treatment of bacterial skin and skin structure infections; Treatment of subjects having bacterial skin or skin structure infection; Treatment of community acquired bacterial pneumonia

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.